- Home
- BCYC
as 07-08-2024 3:30pm EST
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.
| Founded: | N/A | Country: | United Kingdom |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 1.4B | IPO Year: | 2019 |
| Target Price: | $47.25 | AVG Volume (30 days): | 248.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.42 | EPS Growth: | N/A |
| 52 Week Low/High: | $12.54 - $27.50 | Next Earning Date: | 08-01-2024 |
| Revenue: | $41,610,000 | Revenue Growth: | 168.47% |
| Revenue Growth (this year): | 45.38% | Revenue Growth (next year): | -24.87% |
Stock Insider Trading Activity of Bicycle Therapeutics plc (BCYC)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Hannay Michael Charles Ferguson | BCYC | CHIEF PROD & SUPPLY CHAIN OFF | Apr 11 '24 | Sell | $22.49 | 257 | $5,779.93 | 22,891 | SEC Form 4 |
| Lee Kevin | BCYC | CHIEF EXECUTIVE OFFICER | Apr 3 '24 | Sell | $23.81 | 3,158 | $75,191.98 | 387,270 | SEC Form 4 |
| Skynner Michael | BCYC | CHIEF TECHNOLOGY OFFICER | Apr 3 '24 | Sell | $23.81 | 955 | $22,738.55 | 94,884 | SEC Form 4 |
| Keen Nicholas | BCYC | CHIEF SCIENTIFIC OFFICER | Apr 3 '24 | Sell | $23.81 | 790 | $18,809.90 | 62,803 | SEC Form 4 |
| Milnes Alistair | BCYC | CHIEF OPERATING OFFICER | Apr 3 '24 | Sell | $23.81 | 955 | $22,738.55 | 72,241 | SEC Form 4 |
| Crockett Nigel | BCYC | CHIEF BUSINESS OFFICER | Apr 3 '24 | Sell | $23.81 | 955 | $22,738.55 | 47,761 | SEC Form 4 |
| Thompson Travis Alvin | BCYC | CHIEF ACCOUNTING OFFICER | Apr 3 '24 | Sell | $23.81 | 152 | $3,619.12 | 23,223 | SEC Form 4 |
| Thompson Travis Alvin | BCYC | Chief Accounting Officer | Jan 2 '24 | Sell | $17.50 | 604 | $10,570.00 | 23,375 | SEC Form 4 |
| Keen Nicholas | BCYC | Chief Scientific Officer | Jan 2 '24 | Sell | $17.50 | 2,640 | $46,200.00 | 63,593 | SEC Form 4 |
| Crockett Nigel | BCYC | Chief Business Officer | Jan 2 '24 | Sell | $17.50 | 2,643 | $46,252.50 | 48,716 | SEC Form 4 |
| Milnes Alistair | BCYC | Chief Operating Officer | Jan 2 '24 | Sell | $17.50 | 2,643 | $46,252.50 | 73,196 | SEC Form 4 |
| Lee Kevin | BCYC | Chief Executive Officer | Jan 2 '24 | Sell | $17.50 | 8,703 | $152,302.50 | 390,428 | SEC Form 4 |
| Skynner Michael | BCYC | Chief Technology Officer | Jan 2 '24 | Sell | $17.50 | 2,643 | $46,252.50 | 95,839 | SEC Form 4 |
Latest Bicycle Therapeutics plc News
BCYC Breaking Stock News: Dive into BCYC Ticker-Specific Updates for Smart Investing
Zacks
11 days ago
Are Medical Stocks Lagging Bicycle Therapeutics (BCYC) This Year?
Zacks
17 days ago
Top 5 Small-Cap Biotechnology Stocks for a Stable Portfolio
Zacks
a month ago
Is Bicycle Therapeutics (BCYC) Stock Outpacing Its Medical Peers This Year?
CNW Group
a month ago
Hyundai Motor Presents Its First Film 'Night Fishing' in Collaboration with K-Movie Star Son Sukku
PR Newswire
a month ago
IMAGO AIOS Prime Clinches Red Dot Award for 2024, Expands US Footprint with New Boston Warehouse
Business Wire
a month ago
Seibu Ikebukuro Main Store Slated for Summer 2025 Grand Re-opening as a New Department Store
AFP
a month ago
New Zealand scraps plan to tax livestock burps, farts
Business Wire
a month ago
InnoCare Announces Clearance of Clinical Trial of TYK2 Inhibitor ICP-332 by U.S. FDA
Share on Social Networks:
Disclaimer
The information presented on this page, "BCYC Bicycle Therapeutics plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.